These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 32145207)

  • 1. New Drugs Approved in 2019.
    Ebied AM; Patel KH; Cooper-DeHoff RM
    Am J Med; 2020 Jun; 133(6):675-678. PubMed ID: 32145207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Drugs Approved in 2021.
    Ebied AM; Elmariah H; Cooper-DeHoff RM
    Am J Med; 2022 Jul; 135(7):836-839. PubMed ID: 35235820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Drugs Approved in 2022.
    Ebied AM; Elmariah H; Cooper-DeHoff RM
    Am J Med; 2023 Jun; 136(6):545-550. PubMed ID: 36889492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Drug Approvals in 2018 - Another Record Year!
    Ebied AM; Na J; Cooper-DeHoff RM
    Am J Med; 2019 Sep; 132(9):1038-1043. PubMed ID: 30853471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA designations for therapeutics and their impact on drug development and regulatory review outcomes.
    Kesselheim AS; Darrow JJ
    Clin Pharmacol Ther; 2015 Jan; 97(1):29-36. PubMed ID: 25670381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2017 Is Banner Year for Drug Approvals by the Food and Drug Administration.
    Ebied AM; Cooper-DeHoff RM
    Am J Med; 2018 Sep; 131(9):1025-1033. PubMed ID: 29626430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
    Darrow JJ; Avorn J; Kesselheim AS
    JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Drugs Approved in 2020.
    Ebied AM; Elmariah H; Cooper-DeHoff RM
    Am J Med; 2021 Sep; 134(9):1096-1100. PubMed ID: 33939997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A year in review: new drugs for older adults in 2011.
    Vande Griend JP; Marcum ZA; Linnebur SA
    Am J Geriatr Pharmacother; 2012 Aug; 10(4):258-63. PubMed ID: 22682643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021.
    Gupta R; Morten CJ; Zhu AY; Ramachandran R; Shah ND; Ross JS
    JAMA Health Forum; 2022 May; 3(5):e221096. PubMed ID: 35977259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study.
    Kesselheim AS; Wang B; Franklin JM; Darrow JJ
    BMJ; 2015 Sep; 351():h4633. PubMed ID: 26400751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021.
    Monge AN; Sigelman DW; Temple RJ; Chahal HS
    JAMA Netw Open; 2022 Nov; 5(11):e2239336. PubMed ID: 36318210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association between US Food and Drug Administration-expedited review designations and health plan specialty drug coverage.
    Panzer AD; Ingham M; Martin S; Chambers JD
    J Manag Care Spec Pharm; 2023 May; 29(5):464-471. PubMed ID: 36989444
    [No Abstract]   [Full Text] [Related]  

  • 15. Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14: systematic review.
    Wang B; Kesselheim AS
    BMJ; 2015 Sep; 351():h4679. PubMed ID: 26400844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
    Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
    Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugs Cleared Through The FDA's Expedited Review Offer Greater Gains Than Drugs Approved By Conventional Process.
    Chambers JD; Thorat T; Wilkinson CL; Neumann PJ
    Health Aff (Millwood); 2017 Aug; 36(8):1408-1415. PubMed ID: 28784733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-Reported Outcomes Labeling for Products Approved by the Office of Hematology and Oncology Products of the US Food and Drug Administration (2010-2014).
    Gnanasakthy A; DeMuro C; Clark M; Haydysch E; Ma E; Bonthapally V
    J Clin Oncol; 2016 Jun; 34(16):1928-34. PubMed ID: 27069082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unapproved prescription cough, cold, and allergy drug products: recent US Food and Drug Administration regulatory action on unapproved cough, cold, and allergy medications.
    Ostroff C; Lee CE; McMeekin J
    Chest; 2011 Aug; 140(2):295-300. PubMed ID: 21813527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timing of Pediatric Drug Approval and Clinical Evidence Submitted to Regulatory Authorities: International Comparison Among Japan, the United States, and the European Union.
    Hirota S; Yamaguchi T
    Clin Pharmacol Ther; 2020 Nov; 108(5):985-994. PubMed ID: 31869436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.